Precision Peptide Company Inc
BPC.CN
Canadian Securities Exchange0.44
CAD
+0.01
- -
Precision Peptide Company Inc
BPC.CN
(Canadian Securities Exchange)
Recent
price
0.44
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- I cannot browse the web or fetch real-time data in this turn. Please provide the necessary information or allow me to search for the latest publicly available information about Precision Peptide Company Inc (BPC.CN).Precision Peptide Company Inc is a biopharmaceutical company specializing in the research, development, manufacture, and commercialization of peptide-based therapies and diagnostic reagents. The company operates through a core focus on peptide synthesis, customization of peptide sequences, peptide therapeutics development, and related analytical services. It offers contract development and manufacturing services for peptide GMP production, peptide drug discovery support, custom peptide synthesis, and peptide conjugation and formulation capabilities. The company provides analytical testing services, quality control, and regulatory documentation support to ensure compliance with industry standards. Headquartered in [headquarters location], Precision Peptide Company Inc is active in global markets with operations across multiple regions including North America, Europe, and Asia-Pacific. Founded in [founding year], the company maintains dedicated manufacturing facilities, research laboratories, and quality assurance teams to support its customer base in pharmaceutical, biotechnology, and diagnostic sectors. Subsidiaries and partnerships extend its manufacturing capacity and distribution networks, enabling it to serve pharmaceutical manufacturers, academic collaborators, and regional distributors. Latest major company changes include strategic collaborations with biotechnology firms to advance peptide-based therapeutics, recent funding rounds and potential acquisitions to expand manufacturing capabilities, the launch of new peptide platforms and precision synthesis services, and organizational restructurings to align with expanding global operations. There have been notable operational changes in the last 1–2 years, such as facility expansions, increases in production capacity, and the establishment of regional offices to support growing customer demand. Industry and business segments encompass peptide therapeutics development, peptide synthesis and manufacturing, diagnostic reagent supply, and analytical services. Target markets include pharmaceutical and biotech companies, contract research organizations, and research institutions requiring high-purity peptide products and custom synthesis. Geographic operations span North America, Europe, and Asia-Pacific, with potential additional markets as distribution networks grow. The company operates as an independent entity with integrated suppliers and distributors, and maintains partnerships with academic institutions and contract manufacturing partners to support its product and service offerings.